Pfizer and BioNTech announced today that European authorities approved storage of their COVID-19 vaccine at a new temperature.
Based on data showing stability in standard pharmaceutical freezers, the European Medicines Agency (EMA) approved storage of the vaccine at -25°C to -15°C for a total of two weeks. The FDA’s requirements include two-week storage at the same temperatures, with preferred storage set in an ultra-low temperature freezer between -80ºC to -60ºC.
Get the full story at our sister site, Pharmaceutical Processing World.
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.